NICE recommendation for MSD’s Prevymis after re-evaluation
Prevymis is a member of a new class of drugs called non-nucleoside CMV inhibitors.
Read Moreby Anna Smith | Jun 3, 2019 | News | 0
Prevymis is a member of a new class of drugs called non-nucleoside CMV inhibitors.
Read Moreby Selina McKee | Mar 11, 2019 | News | 0
Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting.
Read Moreby Selina McKee | Jan 30, 2018 | News | 0
European regulators have approved MSD’s Prevymis for the prevention of cytomegalovirus (CMV) reactivation and disease in prone adults who have received an allogeneic haematopoietic stem cell transplant (HSCT).
Read Moreby Selina McKee | Nov 13, 2017 | News | 0
MSD’s Prevymis has been green-lighted in the US to prevent cytomegalovirus infection and disease in at-risk adults who have received an allogeneic hematopoietic stem cell transplant (HSCT).
Read Moreby Selina McKee | Nov 13, 2017 | News | 0
The European Medicines Agency’s Committee for Medicinal Products for Human Use has put 10 medicines forward for approval in the region, including new options for multiple sclerosis, eosinophilic esophagitis and eosinophilic asthma.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
